Reprogramming TAMs toward an M1 phenotype, blocking immunosuppressive cytokines with VEGF inhibitors, and engineering DCs to present tumor-specific or neoantigen-derived peptides represent promising approaches to enhance TME remodeling and therapeutic precision (66). This evidence concerns the gene VEGFA and neoplasm.